Triple
T10214857
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CYP2J2 |
E242413
|
entity |
| Predicate | inhibitedBy |
P37861
|
FINISHED |
| Object | ketoconazole |
E850010
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ketoconazole | Statement: [CYP2J2, inhibitedBy, ketoconazole]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ketoconazole Context triple: [CYP2J2, inhibitedBy, ketoconazole]
-
A.
ketoconazole
chosen
Ketoconazole is an imidazole antifungal medication that inhibits ergosterol synthesis and strongly blocks CYP3A4-mediated drug metabolism.
-
B.
itraconazole
Itraconazole is a triazole antifungal medication commonly used to treat systemic and superficial fungal infections and known for significant drug–drug interactions via CYP3A4 inhibition.
-
C.
fluconazole
Fluconazole is a triazole antifungal medication commonly used to treat and prevent a wide range of Candida infections in humans.
-
D.
voriconazole
Voriconazole is a broad-spectrum triazole antifungal medication commonly used to treat serious invasive fungal infections, particularly those caused by Aspergillus species.
-
E.
posaconazole
Posaconazole is a broad-spectrum triazole antifungal medication commonly used to prevent and treat serious invasive fungal infections, particularly in immunocompromised patients.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381ae26c48190985abd0e25ee5d04 |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d4d1f860048190bb20f7d3bf87f347 |
completed | April 7, 2026, 9:44 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d6a7f6730081908b941eaeb6c00993 |
completed | April 8, 2026, 7:09 p.m. |
Created at: April 6, 2026, 11:04 a.m.